SEC Filings

SEC Filings

Select the filing type and date range you wish to view from the drop-down menus below.

NASDAQBLFS
FormDescriptionDateFormat
SCHEDULE 13GSCHEDULE 13GJun 04, 2026Open SCHEDULE 13G in HTML.Open SCHEDULE 13G in DOC file.Open SCHEDULE 13G in PDF file.Open SCHEDULE 13G in XLS file.
8-KReport of unscheduled material events or corporate eventJun 03, 2026Open Report of unscheduled material events or corporate event in HTML.Open Report of unscheduled material events or corporate event in DOC file.Open Report of unscheduled material events or corporate event in PDF file.Open Report of unscheduled material events or corporate event in XLS file.Open Report of unscheduled material events or corporate event in XBLR Viewer.Open Report of unscheduled material events or corporate event in XBLR file.
SCHEDULE 13D/ASCHEDULE 13D/AMay 22, 2026Open SCHEDULE 13D/A in HTML.Open SCHEDULE 13D/A in DOC file.Open SCHEDULE 13D/A in PDF file.Open SCHEDULE 13D/A in XLS file.
144Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stockMay 21, 2026Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in HTML.Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in DOC file.Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in PDF file.Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in XLS file.
4Statement of changes in beneficial ownership of securitiesMay 21, 2026Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
144Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stockMay 20, 2026Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in HTML.Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in DOC file.Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in PDF file.Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in XLS file.
144Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stockMay 19, 2026Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in HTML.Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in DOC file.Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in PDF file.Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in XLS file.
SCHEDULE 13G/ASCHEDULE 13G/AMay 15, 2026Open SCHEDULE 13G/A in HTML.Open SCHEDULE 13G/A in DOC file.Open SCHEDULE 13G/A in PDF file.Open SCHEDULE 13G/A in XLS file.
8-KReport of unscheduled material events or corporate eventMay 07, 2026Open Report of unscheduled material events or corporate event in HTML.Open Report of unscheduled material events or corporate event in DOC file.Open Report of unscheduled material events or corporate event in PDF file.Open Report of unscheduled material events or corporate event in XLS file.Open Report of unscheduled material events or corporate event in XBLR Viewer.Open Report of unscheduled material events or corporate event in XBLR file.
10-QQuarterly report which provides a continuing view of a company's financial positionMay 07, 2026Open Quarterly report which provides a continuing view of a company's financial position in HTML.Open Quarterly report which provides a continuing view of a company's financial position in DOC file.Open Quarterly report which provides a continuing view of a company's financial position in PDF file.Open Quarterly report which provides a continuing view of a company's financial position in XLS file.Open Quarterly report which provides a continuing view of a company's financial position in XBLR Viewer.Open Quarterly report which provides a continuing view of a company's financial position in XBLR file.
SCHEDULE 13G/ASCHEDULE 13G/AMay 06, 2026Open SCHEDULE 13G/A in HTML.Open SCHEDULE 13G/A in DOC file.Open SCHEDULE 13G/A in PDF file.Open SCHEDULE 13G/A in XLS file.
10-K/AAmendment to a previously filed 10-KApr 28, 2026Open Amendment to a previously filed 10-K in HTML.Open Amendment to a previously filed 10-K in DOC file.Open Amendment to a previously filed 10-K in PDF file.Open Amendment to a previously filed 10-K in XLS file.Open Amendment to a previously filed 10-K in XBLR Viewer.Open Amendment to a previously filed 10-K in XBLR file.
4Statement of changes in beneficial ownership of securitiesApr 10, 2026Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
4Statement of changes in beneficial ownership of securitiesApr 10, 2026Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
4Statement of changes in beneficial ownership of securitiesApr 10, 2026Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
4Statement of changes in beneficial ownership of securitiesMar 31, 2026Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
SCHEDULE 13G/ASCHEDULE 13G/AMar 26, 2026Open SCHEDULE 13G/A in HTML.Open SCHEDULE 13G/A in DOC file.Open SCHEDULE 13G/A in PDF file.Open SCHEDULE 13G/A in XLS file.
4Statement of changes in beneficial ownership of securitiesMar 23, 2026Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
4Statement of changes in beneficial ownership of securitiesMar 23, 2026Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
4Statement of changes in beneficial ownership of securitiesMar 23, 2026Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
4Statement of changes in beneficial ownership of securitiesMar 23, 2026Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
4Statement of changes in beneficial ownership of securitiesMar 23, 2026Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
4Statement of changes in beneficial ownership of securitiesMar 23, 2026Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
4Statement of changes in beneficial ownership of securitiesMar 23, 2026Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
144Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stockMar 23, 2026Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in HTML.Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in DOC file.Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in PDF file.Open Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock in XLS file.
1-25      26-50      51-75      76-100      101-125      126-143

We believe the promise of cell and gene therapies starts with the integrity of a single cell

Advancing the future of cell and gene therapy

The human body can heal itself. Cell and gene therapies are designed to augment the patient’s ability to fight disease but only if the living cells behind those therapies remain viable and functional throughout the production processes. At BioLife Solutions, our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. We believe the future of cell and gene therapies hinges on the integrity of every single cell and we are here to protect that promise.

We understand the technical demands of bioprocessing in this field, and our advanced biopreservation expertise, cell culture optimization products, innovative storage systems, and closed-system manufacturing solutions are designed to enhance process efficiency, maintain cellular viability, and ensure reproducibility at every stage. Whether scaling up from R&D, navigating clinical trials or optimizing cryopreservation protocols for commercial production, we provide the tools and experience to streamline your workflow and safeguard your therapies.

Work with experts who understand your biopreservation challenges

Notch-Right-25px
Notch-Bottom-25px

Collaborative and comprehensive CDMO support

At BioLife Solutions, we partner with leading contract development and manufacturing organizations (CDMOs) to enhance their biopreservation and cell processing capabilities. By providing advanced tools, regulatory support, and process optimization strategies, we empower CDMOs to better serve therapy developers, ensuring quality, consistency, and scalability in cell therapy manufacturing.

Regulatory
readiness

Navigating the complex regulatory landscape of cell and gene therapy requires a proactive approach. BioLife Solutions offers experienced regulatory support to help prepare your biopreservation and cell processing methods to meet global standards. From IND and BLA submissions to compliance with GMP, FDA, and EMA guidelines, our solutions help streamline approval pathways.

Notch-Left-25px
Notch-Bottom-25px

STORE

CellSeal®
CryoCase

Alleviate CGT container challenges like fracture risk, bag burping or high rates of particulates

Notch-Right-25px
Notch-Bottom-25px

Data-driven
decision making

Stay ahead with our comprehensive Evidence Library, a curated collection of scientific publications, white papers, and case studies demonstrating the efficacy of BioLife Solutions’ technologies. Access peer-reviewed research, real-world application data, and expert insights to support your bioprocessing and regulatory strategies.

Insights

May 21, 2025

Designing the Ideal Cryostorage Container for CGT

April 18, 2025

The Cell Summit ’25: A Must-Attend Event for Innovators in Cell & Gene Therapy

March 27, 2025

Optimizing Biopreservation Strategies for Apheresis-Derived Cells in Immunotherapeutic Applications

February 19, 2025

How to prepare early for regulatory submissions from IND to BLA

Preserve, protect and expand cell performance

Mastering
Biopreservation

Ensure Regulatory Submission Readiness

Automate & Close
CGT Processes

Protect & Expand
Cell Performance